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Abstract: Obesity is often accompanied by metabolic and haemodynamic disorders such as
hypertension, even during childhood. Arachidonic acid (AA) is metabolized by cytochrome
P450 (CYP450) enzymes to epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid
(20-HETE), vasoactive and natriuretic metabolites that contribute to blood pressure (BP) regulation.
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) omega-3 polyunsaturated fatty acids
may compete with AA for CYP450-dependent bioactive lipid mediator formation. We aimed at
investigating the role of AA, EPA and DHA and their CYP450-dependent metabolites in BP control
and vascular function in 66 overweight/obese children. Fatty acid profile moderately correlated with
the corresponding CYP450-derived metabolites but their levels did not differ between children with
normal BP (NBP) and high BP (HBP), except for higher EPA-derived epoxyeicosatetraenoic acids
(EEQs) and their diols in HBP group, in which also the estimated CYP450-epoxygenase activity was
higher. In the HBP group, EPA inversely correlated with BP, EEQs inversely correlated both with
systolic BP and carotid Intima-Media Thickness (cIMT). The DHA-derived epoxydocosapentaenoic
acids (EDPs) were inversely correlated with diastolic BP. Omega-3 derived epoxymetabolites appeared
beneficially associated with BP and vascular structure/function only in obese children with HBP.
Further investigations are needed to clarify the role of omega-3/omega-6 epoxymetabolites in
children’s hemodynamics.
Keywords: CYP450 eicosanoids; omega-3 PUFA; omega-6 PUFA; blood pressure; hemodynamics;
children; EETs; EEQs
1. Introduction
The prevalence of overweight and obesity in children and adolescents has been increasing in the
last few decades worldwide. Childhood obesity can have serious short- and long-term consequences,
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including metabolic and hemodynamic complications, such as hypertension, insulin resistance and
dyslipidaemia [1].
Beside the impact of body mass index (BMI) per se on blood pressure (BP), several mechanisms
are implicated in hemodynamic control. Dietary habits, in particular, lipid intake can influence not
only body weight but also haemodynamics [2,3]. Indeed, in the last years many studies assessed the
role of different polyunsaturated fatty acids (PUFA), such as arachidonic acid (AA), an omega-6 PUFA
and eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which belong to omega-3 PUFA
family, indicating a beneficial cardiovascular effect of omega-3 PUFA [4,5], whereas it is not clear
whether omega-6 PUFA are cardioprotective or not [6,7]. Several trials and meta-analyses indicated
a possible beneficial effect of omega-3 PUFA supplementation on BP control, although the effect is
modest, and the results of the studies are not always consistent [5,8,9]. Furthermore, omega-3 PUFA
may improve vascular function, that is, arterial stiffness and endothelial function, as supported by
some studies and meta-analysis [10–12], suggesting a possible, at least partial, BP lowering effect of
omega-3 PUFA. We have recently shown, in the same study population, that omega-6 PUFA and in
particular AA are inversely associated with several features of the metabolic syndrome in a sample of
obese children, suggesting their possible protective role [13].
AA, EPA and DHA can be metabolized via cytochrome P-450 (CYP450) into lipid mediators, which
can have profound effects on blood pressure control [2,14], AA can be metabolized by different CYP450
enzymes leading to the formation of several compounds: 5,6-, 8,9-, 11,12-, 14,15-epoxyeicosatrienoic acids
(EETs) via epoxygenase and for example, 20-hydroxyeicosatetraenoic acid (20-HETE) via hydroxylases.
In general, EETs have been shown to play a protective role in cardiovascular diseases through their
anti-inflammatory, vasodilating and sodium excreting effects [15,16]. They are further metabolized
by soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic acids (DHETs), which are less potent
or even inactive compounds. Instead, 20-HETE exerts a natriuretic action at kidney level, but, in the
systemic vasculature, it induces vasoconstriction [17,18]. Linoleic acid (LA) is also metabolized by
CYP450 epoxygenase to 9,10- and 12,13-epoxyoctadecenoic acids (EpOMEs), which are converted
by sEH to 9,10- and 12,13-dihydroxyoctadecenoic acids (DiHOMEs). They have potential toxic
cardiovascular effects, probably mediated by mitochondrial dysfunction and may affect the cardiac
inotropic response but the evidences are rare and diverging [19,20]. Epoxyeicosatetraenoic acids (EEQs),
yielded from EPA, have vasodilating and anti-inflammatory properties and are further metabolized
by sEH to diydroxxyeicosatetraenoic acids (DiHETEs) [21–23]. Epoxydocosapentaenoic acids (EDPs),
derived from DHA via CYP-epoxygenase, are potent vasodilators [23]; they are hydrolysed by sEH
to dihydroxydocosapentaenoic acids (DiHDPAs). Preliminary studies in animal models have shown
that the epoxymetabolites derived from EPA and DHA have a vasodilating action that largely exceeds
that of the AA-derived epoxides [24,25]. EPA and DHA can also be metabolized by CYP-hydroxylase
producing for example, 20-hydroxyeicosapentaenoic acid (20-HEPE) and 22-hydroxydocosahexaenoic
acid (22-HDHA) respectively, whose biological activities are still largely unknown.
Thus, the aim of the present study was to evaluate the possible association between the omega-3
and omega-6 PUFA metabolites via CYP450-epoxygenase/sEH in the modulation of haemodynamic
parameters and especially BP, in a sample of overweight/obese children.
2. Materials and Methods
2.1. Patients and Study Design
Obese children were recruited consequently from October 2012 to September 2014, coming from
the “Paediatric Obesity Outpatients Unit” of the University Hospital of Verona and of the “Local Health
Unit n. 20” of Verona. Inclusion criteria were: children and adolescents aged 5–18 years; overweight
or obesity (BMI ≥ 85th and 95th percentile for sex and age, respectively). We excluded children with
hepatic or renal chronic diseases, malignancies, diabetes mellitus, lipid-lowering or antihypertensive
therapy, secondary causes of obesity.
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The study was conducted according to a cross-sectional observational design.
The study was approved by the Ethical Committee of the University Hospital of Verona
(CE n. 2218) and written informed consent was obtained from each participant’s parents.
2.2. Anthropometric, Blood Pressure and Vascular Assessments
Each child was evaluated in a single occasion, between 8:00 and 9:00 a.m. A questionnaire
was administered to patients and to their parents, dealing with medical history, family history,
physiological and pathological information and use of drugs. Then, the participants underwent a
physical examination. They were advised not to engage in strenuous exercise and to avoid consuming
caffeine containing beverages within 12 h preceding the vascular studies.
During the visit, blood pressure was measured with a semiautomatic oscillometric device
(TM-2551, A&D instruments Ltd., Abingdon Oxford, UK) 3 times, 3 min apart with the patient
lying supine for at least 10 min before the first measurement in a room with controlled temperature
(22–24 ◦C). The mean value of the 3 clinostatic measurements were calculated and considered for
z-score and percentile calculation. Afterward, BP levels were confirmed by a measurement in the
sitting position by the oscillometric device and by auscultatory method. Ambulatory blood pressure
measurement (ABPM) was recorded with an oscillometric device (Spacelabs 90217; Spacelabs Inc.,
Issaquah, WA, USA), which measured BP every 15 min during the day and ever 30 min during the
night. Children and parents recorded physical activities, resting and sleeping time and symptoms on a
dedicated diary. After recording, the daytime and night-time periods (set to default at 7:00 A.M. and
10:00 P.M., respectively) were adapted to “real” awake and sleep times according to what was declared
in the activity diary.
All values derived from BP measurements were transformed in z-score and percentile, according
to normative values [26–28]. The 95th of office and ambulatory BP measurements was used as cut-off
for hypertension, according to current European guidelines [27].
Body weight, height and waist and hip circumferences were measured with the patient wearing
light clothes. Body weight was measured by a calibrated balance and height by a calibrated stadiometer.
Body mass index (BMI) calculated as weight in kg divided by the square of height in m; waist/hip
ratio was calculated as waist circumference in cm divided by hip circumference in cm and waist/height
ratio (WHtR) was calculated as waist circumference in cm divided by height in cm.
Waist circumference was transformed in z-score and percentile according to normative
values [29]. Overweight or obesity were defined for BMI ≥ 90th and 95th percentile for sex and
age, respectively [30]. WHO reference for BMI was used for categorizing children into the overweight
and obese groups [31].
Carotid Intima-media Thickness (cIMT) was assessed by ultrasound of carotid arteries
(LogiQ P5 Pro) and the cIMT was estimated tracking the artery wall in the last centimetre of the
common carotid artery and calculated by a dedicated software (Multimedia Video Engine II (MVE2)
DSP Lab., Pisa CNR, Italy). The relative z-score and percentile were calculated according to reference
values [32].
Endothelial function was assessed by ultrasound of the brachial artery using the Flow Mediated
Dilatation (FMD) technique according to international guidelines and with the aid of a dedicated
hardware (Multimedia Video Engine II (MVE2) DSP Lab., Pisa CNR, Italy) [33]. Common carotid
artery distensibility (DC) was calculated as: DC = ∆A/(A × ∆P) where A is the diastolic lumen area,
∆A is the stroke change in lumen area and ∆P is pulse pressure (PP). Changes in diameters were
detected using ultrasound B-mode image sequences of the right and left common carotid arteries
acquired at different steps and analysed by the above-mentioned automatic system [34]. The relative
z-score and percentile were calculated according to reference values [32].
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2.3. CYP-Derived Eicosanoids Measurement
Plasma samples were subjected to alkaline hydrolysis and subsequent solid phase extraction was
performed as described previously [35].
In brief, 500 µL Methanol, 300 µL 10 molar sodium hydroxide and deuterated internal standards
were added to 500 µL Plasma. The samples were hydrolysed for 30 min at 60 ◦C. The solution
containing free fatty acids and metabolites were neutralized with acetic acid and adjusted to pH = 6.2.
A solid phase extraction procedure using Agilent Bond-Elut-Certify II was performed as formerly
described by Rivera [36].
The LC-ESI-MS/MS method for determination of metabolites was performed by the Lipidomix
GmbH, Berlin Germany, as described previously [35]. The plasma levels of individual metabolites are
given in ng/mL.
Moreover, biomarkers reflecting the endogenous CYP450 epoxygenase and sEH activities were
estimated by calculating the sum of epoxymetabolites plus their corresponding diols or the ratio
between diols and epoxymetabolites.
2.4. Red Blood Cell Membrane Fatty Acids Measurement
EDTA-blood tubes were centrifuged, plasma and buffy coat taken off and erythrocytes frozen at
−80 ◦C until analysis. Erythrocyte fatty acid composition was analysed using the HS-Omega-3
Index® methodology as previously described [37,38]. Fatty acid methyl esters were generated
from erythrocytes by acid transesterification and analysed by gas chromatography using a GC2010
Gas Chromatograph (Shimadzu, Duisburg, Germany) equipped with a SP2560, 100-m column
(Supelco, Bellefonte, PA, USA) using hydrogen as carrier gas. Fatty acids were identified by comparison
with a standard mixture of fatty acids characteristic of erythrocytes. A total of 26 fatty acids were
identified and quantified.
Results are given as percentage of total identified fatty acids after response factor correction.
The coefficient of variation for EPA plus DHA and for most other fatty acids was 4%. Analyses were
quality-controlled according to DIN ISO 15189. All fatty acid determinations were performed by
Omegametrix GmbH, Munich, Germany.
2.5. Statistics
Data are presented as the median and range unless otherwise stated. The statistical analysis was
performed using the software Statistical Package for Social Sciences software (SPSS/PC for Windows
version 21.0; IBM, Armonk, New York, NY, USA). Bivariate nonparametric correlations were estimated
by Spearman coefficient (rS).
Differences in the measured parameters between normotensive and hypertensive children were
analysed by nonparametric (Wilcoxon-Mann-Witney U) tests. A two-tailed test with a p < 0.05 was
considered statistically significant. In order to take into account the multiple comparisons, along with
original p-values, the false discovery rate (FDR) adjusted p-values were also calculated and reported
in the tables, where appropriate.
3. Results
3.1. Patient Characteristics
From the whole study consisting of 72 children we included 66 children (females n: 28; 42%) with
full phenotypic data about eicosanoids, red blood cell membrane FA, ABPM and vascular tests in the
present study.
The collection lasted from October 2012 to October 2014 and included children are 5 to 17 years
old. Four children were overweight (BMI > 90th) and 62 children were obese (BMI > 95th percentile
for sex and age). All children had a central distribution of adiposity (percentile of waist circumference
>90th percentile).
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On the basis of ABPM, we divided the population in two subgroups: high blood pressure (HBP)
(n: 17; 26%) and normal blood pressure (NBP) (n: 49; 74%). In an exploratory analysis we investigated
the correlations of fatty acids and their metabolites with BP and vascular function in each subgroup,
in order to check different associations related to the hypertensive status.
General characteristics of the obese children split by gender and NBP and HBP, diagnosed on
the basis of ABPM (daytime, night-time or 24-hours systolic BP(SBP) or diastolic BP (DBP) ≥ 95th
percentile), are detailed in Table 1. The characteristics of the children divided according to pubertal
status are listed in Table S1.
Table 1. General characteristics of the population divided according to gender and blood pressure status.
Male (n = 38) Female (n = 28) NBP (n = 49) HBP (n = 17)
Variable Median (Range) Median (Range) p-Value * Median (Range) Median (Range) p-Value *
Age, years 11.5 (10.0–14.0) 11.0 (9.0–13.0) 0.187 12.0 (10.0–13.5) 11.0 (8.5–12.5) 0.181
BMI, Kg/m2 28.3 (25.4–31.0) 29.3 (26.1–33.2) 0.392 28.4 (25.7–31.0) 30.4 (26.7–35.3) 0.125
BMI percentile 98.3 (97.2–99.0) 98.7 (97.8–99.3) 0.238 98.0 (97.3–99.0) 99.1 (98.3–99.5) 0.011
Office-SBP, mmHg 119.0 (112.9–125) 116.3 (109.8–129) 0.471 117.0(110.2–110.2)
123.3
(114.5–133.2) 0.031
Office-SBP percentile 83.1 (64.9–94.8) 79.9 (67.7–96.4) 0.697 77.7 (64.7–93.7) 95.6 (76.7–99.3) 0.012
Office-DBP, mmHg 68.3 (63.3–76.1) 66.7 (64.1–72.7) 0.673 66.7 (63.7–72) 75.0 (63.7–77.3) 0.179
Office-DBP percentile 65.1 (43.9–80.7) 66.1 (50.8–77.9) 0.577 64.3 (46.9–76.2) 83.0 (51.4–87.2) 0.033
24 h-SBP, mmHg 118.0 (114–121) 112.0 (107–116) 0.001 ◦ 114.0 (109–118) 121.0(118.5–128.0) <0.001
◦
24 h-SBP, percentile 73.7 (50.6–82.6) 54.4 (35.3–79.8) 0.169 51.7 (37.8–74.6) 90.4 (80.0–98.8) <0.001 ◦
24 h-DBP, mmHg 68.0 (64.0–70.3) 64.0 (61.3–67.0) 0.001 ◦ 65.0 (62.0–68.5) 70.0 (65.5–74.5) 0.002 ◦
24 h-DBP, percentile 57.4 (28.5–74.5) 34.5 (18.7–50.6) 0.007 35.1 (20.0–57.4) 69.9 (42.5–94.5) 0.001 ◦
cIMT, mm 0.46 (0.42–0.51) 0.41 (0.39–0.47) 0.032 0.44 (0.40–0.48) 0.46 (0.42–0.51) 0.179
cIMT, percentile 98.4 (80.3–99.7) 82.3 (60.4–96.7) 0.021 88.2 (59.6–99.1) 96.5 (82.2–99.7) 0.207
cDC, 10−3/Kpa 39.7 (33.5–46.4) 43.8 (34.9–48.3) 0.199 42.0 (34.7–48.5) 37.3 (33.0–42.5) 0.127
cDC, percentile 6.4 (2.4–23.2) 12.8 (2.2–27.0) 0.249 12.3 (2.9–27.0) 4.2 (2.2–13.2) 0.110
Glucose, mg/dL 88.0 (84.0–93.0) 85.0 (79.0–88.0) 0.026 86.0 (83–90) 87.0 (82–93.8) 0.855
Insulin, uU/mL 18.5 (12.4–27.5) 17.8 (13.0–28.2) 0.887 17.7 (11.8–27.6) 24.1 (17.1–30.0) 0.110
Cholesterol, mg/dL 160 (139.9–186.8) 165.0 (134–192) 0.536 165.0 (139–192) 151.5 (132–173.3) 0.297
Triglycerides, mg/dL 79 (55–103.5) 79 (54–100) 0.744 76.5 (54–99.8) 87 (59.5–118) 0.231
FMD, % 7.7 (5.3–10.2) 6.2 (3.4–9.6) 0.403 7.4 (4.2–10.2) 7.6 (3.2–9.8) 0.682
LA, % 11.8 (11.1–12.9) 11.8 (11.1–12.8) 0.841 11.7 (11.0–12.6) 12.4 (11.4–13.1) 0.104
AA, % 16.0 (14.9–17.1) 16.4 (15.8–17.3) 0.082 16.4 (15.6–17.5) 15.5 (14.6–16.6) 0.038
EPA, % 0.4 (0.3–0.5) 0.4 (0.3–0.5) 0.340 0.37 (0.30–0.47) 0.4 (0.3–0.6) 0.127
DHA, % 4.3 (3.8–4.7) 4.4 (3.8–5.0) 0.425 4.4 (3.8–4.8) 4.2 (3.5–4.8) 0.367
Omega-3 Index, % 4.6 (4.1–5.2) 4.6 (4.3–5.5) 0.417 4.6 (4.2–5.3) 4.5 (3.9–5.3) 0.639
EpOMEs, ng/mL 11.2 (8.2–15.9) 10.8 (8.7–15.7) 0.907 11.5 (8.4–15.9) 10.8 (8.3–12.4) 0.613
DiHOMEs, ng/mL 7.2 (5.3–9.7) 6.3 (5.3–8.8) 0.340 6.5 (5.3–9.2) 7.5 (5.6–9.6) 0.363
EpOMEs/DiHOMEs 1.6 (0.9–2.1) 1.6 (1.3–2.4) 0.347 1.7 (1.3–2.3) 1.2 (0.8–1.9) 0.093
EpOMEs+DiHOME 18.6 (14.0–25.7) 18.4 (15.3–22.2) 0.795 19.4 (14.8–23.7) 17.0 (13.4–24.2) 0.634
EETs, ng/mL 7.4 (6.6–8.9) 7.7 (6.8–8.9) 0.460 7.5 (6.6–8.5) 8.4 (7.2–9.2) 0.131
DHETs, ng/mL 4.1 (3.3–4.7) 4.0 (3.5–4.7) 0.726 4.0 (3.4–4.5) 4.0 (3.5–5.1) 0.367
EETs/DHETs 1.9 (1.6–2.4) 2.0 (1.6–1.2) 0.902 1.9 (1.6–2.3) 2.0 (1.6–2.2) 0.814
EETs+DHETs 11.7 (10.1–13.3) 12.1 (10.7–13.2) 0.448 11.8 (10.2–13.0) 12.7 (10.8–14.3) 0.110
EEQs, ng/mL 0.3 (0.2–0.4) 0.4 (0.3–0.5) 0.302 0.3 (0.2–0.5) 0.4 (0.3–0.7) 0.047
DiHETEs, ng/mL 0.9 (0.7–1.3) 0.9 (0.7–1.3) 0.568 0.9 (0.7–1.1) 1.2 (0.9–1.6) 0.021
EEQs/DiHETEs 0.33 (0.31–0.38) 0.42 (0.33–0.54) 0.004 ◦ 0.37 (0.31–0.46) 0.34 (0.31–0.51) 0.872
EEQs+DiHETEs 1.3 (1.0–1.8) 1.3 (0.9–1.8) 0.871 1.2 (1.0–1.5) 1.8 (1.2–2.2) 0.025
EDPs, ng/mL 2.9 (2.4–3.3) 3.2 (2.7–4.2) 0.050 2.9 (2.4–3.3) 3.3 (2.5–3.9) 0.221
DiHDPAs, ng/mL 0.9 (0.8–1.0) 0.9 (0.8–1.1) 0.399 0.9 (0.8–1.1) 0.9 (0.8–1.1) 0.665
EDPs/DiHDPAs 3.3 (2.9–3.6) 3.6 (2.8–4.3) 0.186 3.4 (2.8–3.8) 3.2 (3.0–4.2) 0.878
EDPs+DiHDPAs 3.8 (3.1–4.3) 4.3 (3.5–5.3) 0.044 3.8 (3.3–4.4) 4.3 (3.3–4.9) 0.238
20-HETE 0.74 (0.61–0.86) 0.64 (0.57–0.87) 0.459 0.7 (0.58–0.84) 0.83 (0.53–0.91) 0.553
22-HDHA 0.65 (0.44–0.92) 0.66 (0.41–0.83) 0.721 0.67 (0.42–0.89) 0.64 (0.43–0.91) 0.837
BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, cIMT: carotid intima-media
thickness, cDC: carotid distensibility coefficient, FMD: flow-mediated dilation, LA: Linoleic acid, AA: Arachidonic
acid, EPA: Eicosapentaenoic acid, DHA: Docosahexaenoic acid, Omega-3 Index: (EPA + DHA)/total FA × 100,
EpOME: epoxyoctadecenoic acid, DiHOME: dihydroxyoctadecenoic acid, EET: epoxyeicosatrienoic acid, DHET:
dihydroxyeicosatrienoic acid, EEQ: epoxyeicosatetraenoic acid, DiHETE: dihydroxyeicosatetraenoic acid, EDP:
epoxydocosapentaenoic acid, DiHDPA: dihydroxydocosapentaenoic acid, 20-HETE: 20-hydroxyeicosatetraenoic
acid, 22-HDHA: 22-hydroxydocosahexaenoic acid, HBP: high blood pressure subgroup, NBP: normal blood pressure
subgroup, n: number. 20-hydroxyeicosapentaenoic acid (20-HEPE) plasma concentration was under the limit of
detection. *: Mann-Whitney U-Test; ◦: p < 0.05 after False Discovery Rate correction.
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Girls showed higher BP at ABPM compared to boys. Omega-3 Index, a marker of dietary intake
of long-chain omega-3 PUFA, was 4.61% (2.87–6.61%).
3.2. Omega-6 PUFA
3.2.1. LA and CYP450-Derived Eicosanoids
Associations of LA with Clinical Features and with its Metabolites
LA was similarly distributed according to gender and hypertensive status (Table 1 and Figure 1).
LA directly correlated with DiHOMEs in the whole population and in particular in HBP children
(Table 2 and Figure 2). LA also directly correlates with the estimated CYP450 epoxygenase activity in
HBP (Figure S1).
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DHA; (b) plasma c centration of the CYP450 epoxygenase generated metabolites, that is, pOMEs,
EETs, EEQs and EDPs; (c) the estimated CYP450 epoxygenase activity, calculated as the sum of
epoxymetabolites plus their corresponding diols; (d) the estimated sEH activity, calculated as the
ratio between plasma concentrations (ng/mL) of diols and epoxymetabolites. Data are presented
as mean and SEM. LA: Linoleic acid; AA: Arachidonic acid; EPA: Eicosapentaenoic acid; DHA:
Docosahexaenoic acid; EpOME: epoxyoctadecenoic acid; DiHOME: dihydroxyoctadecenoic acid;
EET: epoxyeicosatrienoic acid; DHET: dihydroxyeicosatrienoic acid; EEQ: epoxyeicosatetraenoic
acid; DiHETE: dihydroxyeicosatetraenoic acid; EDP: epoxydocosapentaenoic acid; DiHDPA:
dihydroxydocosapentaenoic acid; HBP: high blood pressure subgroup; NBP: normal blood pressure
subgroup; sEH: soluble epoxide hydrolase; p: p-value. Vertical lines represent the standard errors.
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Table 2. Correlations between fatty acids (precursors) and the derived eicosanoids via CYP450-
epoxygenase/sEH.
Whole Population NBP HBP
LA
9,10-EpOME 0.102 0.064 0.434
12,13-EpOME 0.094 0.063 0.465
9,10-DiHOME 0.438 ˆ 0.311 * 0.674 ˆ
12,13-DiHOME 0.336 ˆ 0.265 0.659 ˆ
EpOME/DiHOME −0.292 * −0.172 −0.424
EpOME+DiHOME 0.292 * 0.234 0.718 ˆ
AA
5,6-EET 0.029 0.152 −0.049
8,9-EET 0.061 0.162 −0.064
11,12-EET 0.049 0.096 0.177
14,15-EET 0.040 0.114 0.074
5,6-DHET 0.032 0.196 −0.251
8,9-DHET 0.105 0.201 −0.051
11,12-DHET 0.014 0.166 −0.418
14,15-DHET 0.210 0.218 0.220
EET/DHET −0.007 −0.053 0.292
EET+DHET 0.051 0.186 −0.081
EPA
8,9-EEQ 0.434 ˆ 0.267 ◦ 0.784 ˆ,◦
11,12-EEQ 0.575 ˆ 0.482 ˆ,◦ 0.794 ˆ,◦
14,15-EEQ 0.641 ˆ 0.590 ˆ,◦ 0.808 ˆ,◦
17,18-EEQ 0.552 ˆ 0.509 ˆ,◦ 0.643 ˆ,◦
5,6-DiHETE 0.512 ˆ 0.441 ˆ,◦ 0.652 ˆ,◦
8,9-DiHETE 0.398 ˆ 0.337 *,◦ 0.446
11,12-DiHETE 0.217 0.244 −0.023
14,15-DiHETE 0.464 ˆ 0.393 ˆ,◦ 0.532 *,◦
17,18-DiHETE 0.484 ˆ 0.431 ˆ 0.440
EEQ/DiHETE 0.228 0.138 0.521 *,◦
EEQ+DiHETE 0.605 ˆ 0.578 ˆ,◦ 0.652 ˆ
DHA
7,8-EDP 0.482 ˆ,◦ 0.553 ˆ,◦ 0.666 ˆ◦
10,11-EDP 0.375 ˆ,◦ 0.360 *,◦ 0.569 *
13,14-EDP 0.467 ˆ,◦ 0.515 ˆ,◦ 0.563 *
16,17-EDP 0.502 ˆ,◦ 0.591 ˆ,◦ 0.546 *
19,20-EDP 0.456 ˆ,◦ 0.581 ˆ,◦ 0.473
7,8-DiHDPA 0.453 ˆ,◦ 0.521 ˆ,◦ 0.324
10,11-DiHDPA 0.220 0.310 *,◦ 0.205
13,14-DiHDPA 0.256 *,◦ 0.325 *,◦ 0.290
16,17-DiHDPA 0.386 ˆ,◦ 0.531 ˆ,◦ 0.086
19,20-DiHDPA 0.383 ˆ,◦ 0.565 ˆ,◦ 0.010
EDP/DiHDPA 0.150 0.072 0.433
EDP+DiHDPA 0.526 *,◦ 0.617 ˆ,◦ 0.575 *
The table shows the coefficients of correlations (rS) between the fatty acid precursors, namely LA, AA, EPA and DHA
and their metabolites via CYP450-epoxygenase/sEH in the whole sample and in the subgroups of HBP and NBP
children. The underlined correlations remained significant after adjustment for sex, age, pubertal status and BMI.
The sum of epoxymetabolites and corresponding diols estimates the CYP450-epoxygenase activity, whereas their
ratio estimates the sEH activity. *: p < 0.05; ˆ: p < 0.01; ◦: p < 0.05 after False Discovery Rate correction. NBP: normal
blood pressure; HBP high blood pressure; LA: Linoleic acid; AA: Arachidonic acid; EPA: Eicosapentaenoic
acid; DHA: Docosahexaenoic acid; EpHOME: epoxyoctadecenoic acid; DiHOME: dihydroxyoctadecenoic acid;
EET: epoxyeicosatrienoic acid; DHET: dihydroxyeicosatrienoic acid; EEQ: epoxyeicosatetraenoic acid; DiHETE:
dihydroxyeicosatetraenoic acid; EDP: epoxydocosapentaenoic acid; DiHDPA: dihydroxydocosapentaenoic acid.
Nutrients 2018, 10, 1689 8 of 19
Nutrients 2018, 10, x FOR PEER REVIEW  8 of 20 
 
EEQs and EDPs; (c) the estimated CYP450 epoxygenase activity, calculated as the sum of 
epoxymetabolites plus their corresponding diols; (d) the estimated sEH activity, calculated as the ratio 
between plasma concentrations (ng/mL) of diols and epoxymetabolites. Data are presented as mean 
and SEM. LA: Linoleic acid; AA: Arachidonic acid; EPA: Eicosapentaenoic acid; DHA: 
Docosahexaenoic acid; EpOME: epoxyoctadecenoic acid; DiHOME: dihydroxyoctadecenoic acid; 
EET: epoxyeicosatrienoic acid; DHET: dihydroxyeicosatrienoic acid; EEQ: epoxyeicosatetraenoic acid; 
DiHETE: dihydroxyeicosatetraenoic acid; EDP: epoxydocosapentaenoic acid; DiHDPA: 
dihydroxydocosapentaenoic acid; HBP: high blood pressure subgroup; NBP: normal blood pressure 
subgroup; sEH: soluble epoxide hydrolase; p: p-value. Vertical lines represent the standard errors. 
 
Figure 2. Correlations between fatty acids and their metabolite via CYP450-epoxygenase. The graphs 
represent the correlations of the fatty acids with their corresponding epoxymetabolites. The two 
subgroups of obese children with high (HBP) and normal blood pressure (NBP) are differently 
graphically depicted. The panels represent: (a) the correlation of LA with EpOMEs, which was 
stronger in HBP children; (b) the association of AA with EETs; (c) the correlation of EPA with EEQs, 
which was stronger in HBP children; (d) the association of DHA with EDPs. LA: Linoleic acid; AA: 
Arachidonic acid; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid; EpOME: 
epoxyoctadecenoic acid; EET: epoxyeicosatrienoic acid; EEQ: epoxyeicosatetraenoic acid; 
EDP:epoxydocosapentaenoic acid; HBP: high blood pressure subgroup; NBP: normal blood pressure 
subgroup, p: p-value; rS: Spearman correlation coefficient; n.s.: not significant. 
CYP450-Derived Eicosanoids of LA and Their Associations with Clinical Features 
LA did not show any significant correlation with BP (Table 3), whereas DiHOMEs, especially 
9,10-DiHOME, directly correlated with DBP in the whole sample and in the NBP subgroup (Table 4). 
(The associations of the eicosanoids with BP percentiles are reported in Table S2). Vascular tests did 
not show any significant correlation with LA and its metabolites (Table 5). 
Table 3. Correlations between red blood cell membrane fatty acids and BP in the whole study 
population and in the subgroups of HBP and NBP obese children. 
 LA AA EPA DHA 
Whole population 
Office-SBP, mmHg −0.091 −0.070 0.035 0.090 
Office-SBP percentile 0.002 0.002 −0.049 −0.094 
Office-DBP, mmHg 0.168 −0.130 −0.167 −0.106 
i r . rr l ti t f tt i t ir t lit i - . r
r r s t t c rr l ti s f t e fatty acids with their corresponding epoxymetabolites. t
s r s f ese c il re it i ( ) a r al l ress re ( ) are iffere tl
graphically depicted. The panels represent: (a) the correlation of LA with EpOMEs, which was stronger
in HBP children; (b) the association of AA with EETs; (c) the correlation of EPA with EEQs, hich was
stronger in HBP children; (d) the association of DHA with E Ps. LA: Linoleic acid; AA: Arachidonic
acid; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid; EpOME: epoxyoctadecenoic acid;
EET: epoxyeicosatrienoic acid; EEQ: epoxyeicosatetraenoic acid; EDP:epoxydocosapentaenoic acid;
HBP: high blood pressure subgroup; NBP: normal blood pressure subgroup, p: p-value; rS: Spearman
correlation coefficient; n.s.: not significant.
CYP450-Derived Eicosanoids of LA and Their Associations with Clinical Features
LA did not show any significant correlation with BP (Table 3), whereas DiHOMEs, especially
9,10-DiHOME, directly correlated with DBP in the whole sample and in the NBP subgroup (Table 4).
(The associations of the eicosanoids with BP percentiles are reported in Table S2). Vascular tests did
not show any significant correlation with LA and its metabolites (Table 5).
Table 3. Correlations between red blood cell membrane fatty acids and BP in the whole study
population and in the subgroups of HBP and NBP obese children.
LA AA EPA DHA
hole population
Office-SBP, mmHg −0.091 −0.07 0.035 0.090
Office-SBP percentile 0.0 2 0.002 −0.049 −0.094
Office-DBP, mmHg 0.168 −0.130 −0.167 −0.106
Office-DBP percentile 0.217 −0.095 −0.175 −0.210
24 h-SBP, mmHg 0.096 −0.329 ˆ 0.154 0.016
24 h-SBP percentile 0.229 −0.134 0.014 −0.214
24 h-DBP, mmHg 0.171 −0.222 −0.069 −0.140
24 h-DBP percentile 0.200 −0.176 −0.092 −0.175
Day-time SBP, mmHg 0.070 −0.277 * 0.172 0.043
Day-time SBP, percentile 0.192 −0.129 0.086 −0.132
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Table 3. Cont.
LA AA EPA DHA
Whole population
Day-time DBP, mmHg 0.136 −0.132 −0.075 −0.142
Day-time DBP, percentile 0.136 −0.092 −0.084 −0.142
Night-time SBP, mmHg 0.066 −0.327 ˆ 0.154 −0.001
Night-time SBP, percentile 0.213 −0.178 0.051 −0.121
Night-time DBP, mmHg 0.145 −0.359 ˆ 0.014 −0.046
Night-time DBP, percentile 0.159 −0.353 ˆ 0.043 −0.040
HBP
Office-SBP, mmHg 0.013 0.088 −0.639 ˆ −0.050
Office-SBP percentile 0.017 0.172 −0.609 ˆ −0.113
Office-DBP, mmHg 0.206 −0.136 −0.564 * −0.377
Office-DBP percentile 0.218 0.083 −0.668ˆ −0.157
24 h-SBP, mmHg −0.425 0.220 −0.111 0.236
24 h-SBP percentile −0.279 0.387 −0.043 0.250
24 h-DBP, mmHg −0.278 −0.205 −0.251 0.010
24 h-DBP percentile −0.228 −0.184 −0.269 −0.012
Day-time SBP, mmHg −0.433 0.055 0.013 0.257
Day-time SBP, percentile −0.277 0.306 0.037 0.257
Day-time DBP, mmHg −0.263 −0.167 −0.164 0.001
Day-time DBP, percentile −0.252 −0.142 −0.188 0.015
Night-time SBP, mmHg −0.413 0.319 −0.225 0.172
Night-time SBP, percentile −0.193 0.466 −0.029 0.076
Night-time DBP, mmHg −0.258 −0.182 −0.427 −0.021
Night-time DBP, percentile −0.228 −0.191 −0.426 −0.049
NBP
Office-SBP, mmHg −0.180 −0.034 0.169 0.188
Office-SBP percentile −0.087 0.042 0.063 −0.050
Office-DBP, mmHg 0.089 −0.144 −0.049 0.025
Office-DBP percentile 0.128 −0.111 −0.079 −0.125
24 h-SBP, mmHg 0.059 −0.325 * 0.060 0.057
24 h-SBP percentile 0.217 −0.037 −0.163 −0.311 *
24 h-DBP, mmHg 0.233 −0.221 −0.131 −0.151
24 h-DBP percentile 0.268 −0.172 −0.159 −0.196
Day-time SBP, mmHg 0.062 −0.268 0.092 0.067
Day-time SBP, percentile 0.184 −0.069 −0.058 −0.160
Day-time DBP, mmHg 0.208 −0.124 −0.136 −0.176
Day-time DBP, percentile 0.209 −0.060 −0.147 −0.176
Night-time SBP, mmHg 0.052 −0.335 * 0.090 0.025
Night-time SBP, percentile 0.249 −0.154 −0.042 −0.212
Night-time DBP, mmHg 0.229 −0.340 * −0.044 −0.025
Night-time DBP, percentile 0.251 −0.333 * −0.027 −0.035
The table shows the spearman coefficients of correlations (rs) between fatty acids (precursors), namely LA,
AA, EPA, DHA and office and ambulatory BP in the whole sample and in the subgroups of HBP and NBP
children. The underlined correlations remained significant after adjustment for sex, age, pubertal status and BMI.
*: p < 0.05; ˆ: p < 0.01 after False Discovery Rate correction. NBP: normal blood pressure; HBP high blood pressure;
AA: arachidonic acid; DHA: docosahexaenoic acid; DBP: diastolic blood pressure; EPA: eicosapentaenoic acid;
LA: linolenic acid; SBP: systolic blood pressure.
Nutrients 2018, 10, 1689 10 of 19
Table 4. Correlations of CYP450-epoxygenase/sEH metabolites of LA, AA, EPA and DHA with BP in the whole study population and in the two subgroups of high
blood pressure and normal blood pressure obese children.
Office SBP, mmHg Office DBP, mmHg 24-h SBP, mmHg 24-h DBP, mmHg Day-time SBP,mmHg
Day-time DBP,
mmHg
Night-time SBP,
mmHg
Night-time DBP,
mmHg
Whole population
EpOMEtot −0.092 0.070 −0.025 0.069 −0.045 0.073 −0.086 −0.019
DiHOME tot −0.060 0.279 *9,10-DiHOME 0.319 ˆ 0.031 0.149 −0.053 0.052 0.103
0.252 *
9,10-DiHOME 0.256 *
EET tot 0.060 −0.008 0.019 0.037 0.004 0.040 0.017 −0.044
DHET tot 0.142 0.052 0.036 0.006 0.077 0.050 0.012 −0.020
EEQ tot −0.120 −0.2118,9-EEQ −0.307 * 0.045 0.030 0.038 0.021 0.052 −0.076
DiHETE tot −0.069 −0.171 0.117 0.109 0.131 0.058 0.080 0.112
EDP tot −0.128 −0.180 −0.013 −0.077 0.001 −0.067 −0.076 −0.140
DiHDPA tot −0.035 −0.077 −0.028 −0.086 0.030 −0.054 −0.161 −0.134
HBP
EpOME tot −0.256 −0.094 −0.315 −0.291 −0.428 −0.380 −0.271 0.068
DiHOME tot −0.104 0.232 −0.252 −0.098 −0.363 −0.123 −0.266 0.037
EET tot −0.108 −0.287 −0.211 0.071 −0.087 0.183 −0.311 0.106
DHET tot −0.016 −0.109 −0.034 −0.050 0.112 0.046 −0.102 −0.047
EEQ tot
−0.539 *
11,12-EEQ −0.694 ˆ
17,18-EEQ −0.584 *
−0.299 −0.27611,12-EEQ −0.492 * −0.117 −0.080 −0.038
−0.439
11,12-EEQ −0.559 *
17,18-EEQ −0.615 ˆ
−0.216
DiHETE tot −0.43717,18-DiHETE −0.578 * −0.120
−0.233
17,18-DiHETE −0.512 * 0.142 −0.076 0.205
−0.348
17,18-DiHETE −0.492 * 0.089
EDP tot
−0.229
7,8-EDP −0.574 *
10,11-EDP −0.506 *
16-17-EDP−0.539 *
−0.526* −0.120 −0.284 −0.010 −0.205 −0.361 −0.240
DiHDPA tot −0.090 −0.382 0.093 −0.183 0.277 −0.070 −0.195 −0.350
NBP
EpOME tot −0.048 0.148 0.065 0.147 0.070 0.206 −0.049 −0.033
DiHOME tot −0.094 0.2819,10-DiHOME 0.319 * 0.027 0.158 −0.054 0.062 0.141
0.313 *
9,10-DiHOME 0.312 *
EET tot 0.057 −0.003 −0.029 −0.076 −0.043 −0.064 −0.121 −0.2648,9-EET −0.332 *
DHET tot 0.189 0.104 −0.013 0.013 0.025 0.034 −0.071 −0.044
EEQ tot −0.080 −0.143 −0.073 −0.024 −0.070 −0.013 −0.104 −0.27914,15-EEQ −0.297 *
DiHETE tot −0.065 −0.21111,12-DiHETE −0.339 * −0.003 −0.018 0.023 −0.089 −0.095 −0.086
EDP tot −0.156 −0.090 −0.078 −0.084 −0.059 −0.072 −0.25119,20-EDP −0.303 * −0.259
DiHDPA tot −0.018 −0.009 −0.094 −0.068 −0.050 −0.067 −0.280 −0.143
The table shows the coefficients of correlations (rs) between the metabolites of LA, AA, EPA, DHA via CYP450-epoxygenase/sEH and office and ambulatory BP in the whole sample and in
the subgroups of HBP and NBP children. The underlined correlations remained significant after adjustment for sex, age, pubertal status and BMI. *: p < 0.05; ˆ: p < 0.01. NBP: normal
blood pressure; HBP high blood pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure; EpOME: epoxyoctadecenoic acid; DiHOME: dihydroxyoctadecenoic acid; EET:
epoxyeicosatrienoic acid; DHET: dihydroxyeicosatrienoic acid; EEQ: epoxyeicosatetraenoic acid; DiHETE: dihydroxyeicosatetraenoic acid; EDP: epoxydocosapentaenoic acid; DiHDPA:
dihydroxydocosapentaenoic acid.
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Table 5. Correlations of LA, AA, EPA, DHA and the derived CYP450-epoxygenase/sEH metabolites with
vascular tests in the whole sample and in the two individual subgroups of HBP and NBP obese children.
cIMT cIMT, (Percentile) DC DC, (Percentile) FMD, %
Whole population
LA 0.112 0.143 0.119 0.094 −0.150
AA −0.142 −0.097 0.108 0.063 −0.005
EPA −0.212 −0.305 * −0.067 −0.015 0.176
DHA −0.071 −0.170 −0.106 −0.053 0.139
EpOMEs 0.069 0.064 0.120 0.140 −0.141
DiHOMEs −0.083 −0.077 0.095 0.085 −0.155
EETs 0.093 0.084 0.072 0.073 −0.185
DHETs −0.070 −0.045 −0.058 −0.052 −0.049
EEQs −0.184
−0.230
14,15-EEQ −0.279 *
17,18-EEQ −0.263 *
0.069 0.096 −0.008
DiHETEs 0.008 −0.026 0.012 0.024 0.176
EDPs −0.082 −0.119 0.136 0.147 −0.158
DiHDPAs −0.171 −0.206 0.091 0.121 −0.101
HBP
LA −0.121 −0.025 0.175 0.207 −0.400
AA −0.172 −0.174 0.011 −0.039 −0.121
EPA −0.304 −0.378 0.432 0.407 0.268
DHA 0.027 −0.002 −0.121 −0.136 −0.146
EpOMEs −0.063 0.034 0.050 0.093 −0.050
DiHOMEs 0.067 0.071 −0.132 −0.132 0.004
EETs −0.231 −0.061 0.314 0.214 0.118
DHETs −0.301 −0.273 0.155 0.071 0.296
EEQs
−0.605 *
8;9-EEQ −0.493 *
14;15-EEQ −0.609 ˆ
17;18-EEQ −0.615*
−0.620 ˆ
8;9-EEQ −0.539 *
14;15-EEQ −0.657 ˆ
17;18-EEQ −0.637 ˆ
0.374
11;12-EEQ 0.575 *
0.388
11;12-EEQ 0.582 * 0.288
DiHETEs −0.3545;6-DiHETE −0.559 *
−0.323
5;6-DiHETE −0.577 * 0.290 0.209
0.375
5;6-DiHETE −0.576 *
EDPs −0.098 0.002 0.312 0.237 −0.220
DiHDPAs −0.114 −0.104 0.148 0.086 −0.091
NBP
LA 0.142 0.181 0.132 0.108 −0.082
AA −0.067 −0.016 0.088 0.043 0.029
EPA −0.243 −0.359 * −0.174 −0.099 0.137
DHA −0.097 −0.217 −0.137 −0.061 0.248
EpOMEs 0.095 0.078 0.107 0.140 −0.189
DiHOMEs −0.163 −0.145 0.196 0.186 −0.209
EETs 0.159 0.101 0.032 0.068 −0.272
DHETs 0.010 0.025 −0.103 −0.091 −0.165
EEQs −0.162 −0.23514,15-EEQ −0.308 * 0.013 0.046 −0.116
DiHETEs 0.050 −0.014 −0.024 0.019 0.155
EDPs −0.185 −0.24719,20-EDP −0.296 * 0.081 0.121 −0.067
DiHDPAs 0.223 0.259 0.195 0.180 −0.095
The table shows the spearman coefficients of correlations (rS) between LA, AA, EPA, DHA and their metabolites
via CYP450-epoxygenase/sEH with the vascular tests and their percentiles for sex and age in the whole
sample and in the subgroups of HBP and NBP children. The underlined correlations remained significant after
adjustment for sex, age, pubertal status and BMI. * p< 0.05; ˆ p < 0.01. NBP: normal blood pressure; HBP high
blood pressure; AA: arachidonic acid; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; LA: linolenic
acid; EpOME: epoxyoctadecenoic acid; DiHOME: dihydroxyoctadecenoic acid; EET: epoxyeicosatrienoic acid;
DHET: dihydroxyeicosatrienoic acid; EEQ: epoxyeicosatetraenoic acid; DiHETE: dihydroxyeicosatetraenoic acid;
EDP: epoxydocosapentaenoic acid; DiHDPA: dihydroxydocosapentaenoic acid; cIMT: carotid intima-media
thickness; cDC: carotid distensibility; FMD: flow-mediated dilation.
3.2.2. AA and CYP450-Derived Eicosanoids
Associations of AA with Clinical Features and with Its Metabolites
AA was higher in NBP as compared to HBP children (Table 1 and Figure 1). In the whole sample,
AA was inversely correlated to ABPM and this inverse association was confirmed in the NBP subgroup
(Table 3). No significant correlations were found between AA and vascular features (Table 5).
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Considering the metabolic pathway of AA via CYP450 and sEH, AA was not significantly
correlated with its metabolites via CYP450/sEH neither in the whole population nor in the subgroups
of HBP and NBP children (Table 2 and Figure 2). AA did not show any significant difference also with
the estimated CYP450 epoxygenase activity (Figure S1).
CYP450-Derived Eicosanoids of AA and Their Associations with Clinical Features
EETs and DHETs, the epoxymetabolites and the corresponding diols derived from AA
respectively, did not show any significant association with BP and vascular function markers
(Tables 4 and 5. The associations of the eicosanoids with BP percentiles are detailed in Table S2).
Twenty-hydroxyeicosatetraenoiic acid (20-HETE), the hydroxymetabolite of AA, did not differ between
HBP and NBP subgroups (Table 1) and did not show any significant correlation with BP and
vascular features.
3.3. Omega-3 PUFA
3.3.1. EPA and CYP450-Derived Eicosanoids
Associations of EPA with Clinical Features and with Its Metabolites
The amount of EPA in red blood cell membrane was similar in both groups of HBP and NBP
obese children (Table 1 and Figure 1). EPA inversely correlated with office BP and with cIMT in the
HBP subgroup and the inverse correlation with cIMT was significant also in the whole population
(Tables 3 and 5).
EPA was directly correlated with its epoxymetabolites and the corresponding diols, especially the
14,15-isomer, in the whole sample and in both subgroups (Table 2). In the subgroup of HBP children
the strength and the slope of the correlations between the precursor and the products were higher
and EEQs and DiHETEs were more elevated than in NBP (Figure 2). Moreover, the estimated CYP450
activity (sum of EEQs and DiHETEs) was higher in the HBP than in NBP children (Figure 1 panel (c))
and EPA correlated stronger with the estimated CYP450 activity in the HBP than in NBP subgroup,
whereas the estimated sEH activity did not differ between the two groups (Table 2 and Figure S1).
CYP450-Derived Eicosanoids of EPA and Their Associations with Clinical Features
EEQs and DiHETEs inversely correlated with office and ambulatory BP, in particular 11,12-EEQ
and 17,18-DiHETE (Table 4 and Figure 3. The associations of the eicosanoids with BP percentiles
are reported in Table S2). In the whole sample, only 8,9-EEQ showed an inverse correlation
with office DBP (Table 4.). The epoxymetabolites of EPA inversely correlated also with cIMT,
in particular 14,15- and 17,18- EEQ (Figure 3) and these associations were more evident in the
HBP group, in which also 5,6-DiHETE sowed an inverse correlation with cIMT. In this subgroup
11,12-EEQ was also directly correlated with carotid distensibility (Table 5). Plasma concentration of
twenty-hydroxyeicosapentaenoic acid (20-HEPE), the hydroxymetabolite of EPA, was under the limit
of detection.
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3.3.2. DHA and CYP450-Derived Eicosanoids
Associations of DHA with Clinical Features and with Its Metabolites
DHA had a similar distribution among genders and hypertensive status (Table 1) and was
associated neither with BP nor with the main vascular features (Tables 3 and 5).
DHA was directly correlated with its epoxymetabolites, the EDPs, in the whole population and in
both subgroups and was directly correlated with DiHDPAs in particular in NBP children (Table 2 and
Figure 2). DHA directly correlated with the estimated CYP450 epoxygenase activity in both subgroups
(Figure S1).
CYP450-Derived Eicosanoids of EPA and Their Associations with Clinical Features
EDPs and DiHDPAs were not associated with BP and vascular features, except an inverse
correlation of most isomers of EDPs with office SBP in HBP children (Table 4. The associations
of the eicosanoids with BP percentiles are detailed in Table S2). Plasma concentrations of
22-hydroxydocosahexaenoic acid (22-HDHA) did not differ between HBP and NBP subgroups (Table 1)
and did not show any significant correlation with BP and vascular characteristics, except an inverse
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correlation with cIMT (rS = −0.292, p < 0.01) and the relative z-score (rS = −0.297, p < 0.01) in the
NBP subgroup.
Most of the above-mentioned significant correlations remained significant after adjustment for sex,
age and pubertal status, as indicated in the relative tables. After False Discovery Rate (FDR) correction
only most of the correlations between the precursors and the respective products remained significant.
4. Discussion
Our main hypothesis was that several PUFA, mainly assumed by the diet, could affect
hemodynamics and in particular blood pressure, through the formation of specific PUFA-derived lipid
mediators generated via the CYP450-epoxygenase/sEH pathway. Scarce is the evidence linking the
amount of fatty acids introduced by diet and their metabolites via CYP450/sEH with hemodynamics
in humans and, to our knowledge, this is the first study that investigated this link in children. Indeed,
red blood cell membrane fatty acids are a reliable marker of dietary intake, especially for essential fatty
acids, reflecting the preceding intake of the fatty acid [38].
A complex link between PUFA and BP is supported by the literature, where the putative beneficial
effect of omega-3 PUFA on BP and subsequent cardiovascular events is often blurred, being evident in
some trials but not in others or in meta-analyses [5,39], with some studies also available in children [40–42].
The underlying mechanisms are multifactorial and may include an improvement in endothelial function
and in arterial stiffness [10–12], although the relative effects of omega-3 PUFA and their CYP450 generated
metabolites remain not completely understood.
Despite plenty of studies in animal models [43], especially rats, the evidence that EETs could
affect BP in humans is scanty. In particular, our group found lower plasma EETs in patients affected by
renovascular hypertension as compared to essential hypertension and controls [44] and an augmented
production of EETs in plasma and placentas obtained by preeclamptic women [45,46]. Surprisingly,
we did not find any association of EETs neither with BP nor vascular function in this sample of
obese children.
Little is known about the specific actions of the EPA/DHA-derived metabolites via CYP450/sEH
on hemodynamic modulation both in animal models and humans but a few studies support a protective
effect on blood pressure, at least for some single isomers [23,25] suggesting that their actions could be
even more potent with respect to EETs.
In this study, we found interesting correlations between EPA and DHA and the corresponding
metabolites via CYP450-epoxygenase, supporting the hypothesis that a dietary assumption of specific
omega-3 PUFA (or at least a higher storage in cellular membranes) drives a higher production of
their metabolites. Interestingly, these metabolic steps appear different in HBP and in NBP children.
Indeed, the association between precursor and products, especially for EPA metabolism, is stronger
and steeper in HBP than in NBP and, moreover, also the estimated CYP450-epoxygenase activity
(sum of epoxides and diols) itself is higher in HBP children whereas no difference in the estimated
sEH activity (epoxide/diol ratio) was evident between the two subgroups. These data suggest that in
HBP obese children the CYP450-epoxygenase, in particular for EPA, might have a different efficacy or
regulation as compared to NBP. We could hypothesize that in obese children with HBP is a modulation
in CYP450-epoxygenase activity, rather than in sEH activity, leading to an enhanced formation of the
epoxymetabolites, which are supposed to have more favourable cardiovascular effects.
Furthermore, the exploratory analyses in the subgroup of HBP children, seems to reveal a potential
role of some metabolites (especially EEQs and EDPs) on BP. Especially EEQs and in particular 14,15-
and 17,18- EEQ, showed inverse associations with several BP measurements and with the markers
of vascular structure and function (namely, cIMT and distensibility) in HBP obese children. Even if
this is only an exploratory analysis and should be examined with caution, it is compatible with the
hypothesis that the effect of endothelium derived hyperpolarizing factors (such as EETs/EEQs/EDPs)
is detectable only in circumstances when the effect of nitric oxide (NO) is altered [47,48]. Indeed,
some of the beneficial cardiovascular effects of long-chain omega-3 PUFA and especially EPA, at least
Nutrients 2018, 10, 1689 15 of 19
those mediated by CYP450/sEH metabolites, could act as compensatory mechanism and thus being
more evident in more disadvantageous conditions, that is, obesity together with high blood pressure.
Only a few studies addressed this issue: a study in transgenic mice with endothelial expression of the
human CYP2J2 and CYP2C8 demonstrated that increased endothelial CYP450 epoxygenase expression
reduced BP increase especially when nitric oxide synthase and cyclooxygenase were inhibited [49].
Data from studies in humans also support the hypothesis that the CYP450 pathways compensate
the impairment of vasodilation due to classical pathways, like NO, for example in hypertensive
patients [47] and in subjects with hyperpathyroidism, which is generally associated with high blood
pressure and an increased CV risk [50].
In line with our observations, also some other studies suggest that EPA and DHA exert a stronger
effect in hypertensive as compared to normotensive subjects, as suggested also by meta-analyses [5,39,51].
Interestingly, the inverse association of 14,15- and 17,18-EEQ with cIMT, is even stronger in the HBP
subgroup compared to the whole group as well.
The observational study design and the exploratory analyses suggest looking at all these
associations with caution. Anyhow, we hypothesize that EPA could exert a somehow protective
action on blood pressure through their metabolites via CYP450-epoxygenase/sEH, probably mediated
by a beneficial influence on vascular structure and function and this effect could be stronger in HBP
obese children than in NBP. The stronger correlations of EPA with its metabolites in HBP rather than
in NBP children support the hypothesis that their effect becomes more important when BP is higher.
Interestingly, DiHOME, the diols derived from LA via CYP450 and sEH metabolism, showed
a direct correlation with diastolic BP in NBP but not in HBP, suggesting that they negatively affect
vascular stiffness and BP but only in normotensive obese children. Very little is known about the actions
of EpOMEs and DiHOMEs; first data indicated a toxic effect of EpOME and probably of DiHOME
that could be dose-dependent; they also could affect cardiac contractility but the results are not always
consistent [12,13]. On the other hand, a recent study has proposed a possible protective effect of
12,13-DiHOME on metabolic profile, due to its action on brown adipose tissue uptake of fatty acids [52].
Furthermore, an epoxy-keto derivative of LA has been identified as a possible stimulating factor for
aldosterone secretion but its precursor and its metabolic pathway is not known [53]. Furthermore,
we found that LA was inversely correlated to BP in HBP subjects, suggesting a possible beneficial
effect of LA on BP. These data are not easy to interpret, considering the results of the metabolite of
LA, especially the possible positive role of 12,13-DiHOME. Anyhow, it should be considered that from
each fatty acid derives a range of lipid mediators, which can have different actions. Moreover, also in a
previous animal model a discrepancy has been found regarding the effect of dietary intake of fatty
acids, that is, LA and ALA, on the composition of PUFA and their related metabolites [54].
As mentioned above, the present study has limitations: the lack of data about the total food intake
of fatty acids and the amount of fatty acids in the diet, the sample size is relatively low, which can
primarily expose a problem of statistical power; after statistical adjustment for multiple testing only
several correlations remained significant. Thus, considering also the observational design of the study,
the results should be regarded as exploratory and need confirmation in new studies. Furthermore,
we decided to define hypertension on the basis of a single ABPM registration, considering it being
more accurate to establish hypertension based on a single exam. Finally, these results need to be
confirmed in other studies analysing also samples of children of different ages and body size, including
non-obese children and different ethnic groups.
Anyhow, we obtained also several office BP measurements, both in the supine position and in the
recommended sitting position, which strengthened the results derived from ABPM.
Globally, our data suggest that single lipid mediators may exert specific actions in hemodynamic
control in obese children, that may be different in hypertensive rather than in normotensive children.
What remains to be understood are the regulatory mechanisms that can modulate the metabolic
pathways of the fatty acids, leading to the production of specific lipid mediators. Moreover, also the
relations, or the competition, between different metabolic pathways might affect the productions of
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active metabolites, thus influencing the final effect [2]. Furthermore, the omega-3 index of the obese
children included in this study was quite low (mean: 4.6%), far below the proposed target of 8% or
more, which is suggested as CV protective level by the evaluation of epidemiological and clinical
studies [55,56]. Thus, another question that should be addressed by future studies is whether obese
children with HBP may benefit from dietary EPA/DHA supplementation.
In conclusion, this study sets out the steps to further investigate, in children as well in
adults, the metabolism of dietary fatty acids, especially via CYP450 and their possible influence
on hemodynamics and BP control.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/11/
1689/s1, Table S1: General characteristics of the obese children divided according to pubertal status, Table S2:
Correlations of CYP450-epoxygenase/sEH metabolites of LA, AA, EPA and DHA with BP percentiles in the whole
sample and in the two subgroups of HBP and NBP obese children, Figure S1: Correlations between fatty acids
and the estimated CYP450-epoxygenase activity.
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